Aldeyra Therapeutics (ALDX) Price & Analysis

Compare

1,659 Followers

ALDX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.14 - $7.20

Previous CloseN/A

Volume102.94K

Average Volume (3M)1.13M

Market Cap

$322.84M

Enterprise Value$126.91M

Total Cash (Recent Filing)$81.92T

Total Debt (Recent Filing)$15.56T

Price to Earnings (P/E)―

Beta3.17

Next Earnings

Apr 30, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding59,895,588

10 Day Avg. Volume917,297

30 Day Avg. Volume1,130,638

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.39

Enterprise Value/Revenue518.99

Enterprise Value/Gross Profit-1.99K

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$9.50

Price Target Upside76.25% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

FDA Approval ProcessThe announced FDA acceptance of the resubmitted NDA for lead asset Reproxalap is seen as a positive step towards getting approval for treating dry eye disease.

Strategic PartnershipsThe option agreement with AbbVie for a potential co-exclusive license in the US market is seen as a strong strategic move, given AbbVie's existing salesforce and market position.

Treatment EfficacyReproxalap's fast benefit measured in minutes offers a significant advantage over standard dry eye treatments.

Bears Say

Approval AssuranceAn SPA doesn't guarantee approval if the trial is positive, but it's as close as the agency ever gets to this type of assurance.

Data LimitationsThe NDA resubmission package contains only data from the chamber trial, which means that it does not include data from the negative field trial.

Market CompetitionDespite its rarity, the significant disease burden and a lack of competing treatment options makes the PVRL market worth looking at.

Aldeyra Therapeutics News

Aldeyra receives orphan designation for ADX-2191 from EMA

Aldeyra (ALDX) announced that the European Medicines Agency has granted orphan designation for ADX-2191 for the treatment of...

24d ago

ALDX

Aldeyra Therapeutics: Positive NDA Resubmission and Strategic Advancements Support Buy Rating

Analyst Marc Goodman from Leerink Partners maintained a Buy rating on Aldeyra Therapeutics and keeping the price target...

2d ago

ALDX

Buy Rating for Aldeyra Therapeutics Driven by FDA Progress and Strategic Partnership Potential

H.C. Wainwright analyst Matthew Caufield has reiterated their bullish stance on ALDX stock, giving a Buy rating on...

6d ago

ALDX

FDA Accepts Aldeyra’s Reproxalap Application for Review

Aldeyra Therapeutics ( ($ALDX) ) has provided an update. On July 17, 2025, Aldeyra Therapeutics announced that the...

1M ago

ALDX

Aldeyra announces FDA acceptance for review of reproxalap NDA

Aldeyra (ALDX) announced that the FDA has accepted for review the resubmitted new drug application for topical ocular...

1M ago

ALDX

Aldeyra Therapeutics: Positioned for Success with ADX-2191 and Strategic Portfolio Expansion

BTIG analyst Thomas Shrader has maintained their bullish stance on ALDX stock, giving a Buy rating yesterday. Thomas...

2M ago

ALDX

Aldeyra Therapeutics Receives FDA Protocol Agreement for ADX-2191

Aldeyra Therapeutics ( ($ALDX) ) has shared an announcement. On June 26, 2025, Aldeyra Therapeutics announced that it...

2M ago

ALDX

Aldeyra receives special protocol assessment agreement letter from FDA

Aldeyra (ALDX) announced receipt of a special protocol assessment agreement letter from the FDA for ADX-2191, an investigational...

2M ago

ALDX

Aldeyra Therapeutics: Buy Rating Affirmed Amidst Promising Developments in Dry Eye Disease Treatment and Strategic Partnerships

In a report released on June 18, Thomas Shrader from BTIG maintained a Buy rating on Aldeyra Therapeutics...

2M ago

ALDX

Aldeyra Resubmits Reproxalap NDA to FDA

An update from Aldeyra Therapeutics ( ($ALDX) ) is now available. On June 17, 2025, Aldeyra Therapeutics announced...

2M ago

ALDX

Aldeyra resubmits topical ocular reproxalap NDA to FDA

Aldeyra (ALDX) announced the resubmission of a new drug application to the FDA for topical ocular reproxalap, an...

2M ago

ALDX

Aldeyra Therapeutics Holds Annual Meeting with Key Votes

Aldeyra Therapeutics ( ($ALDX) ) just unveiled an update. At the Aldeyra Therapeutics annual meeting held on June...

2M ago

ALDX

Aldeyra Therapeutics: Strong Financial Position and Positive Trial Outcomes Drive Buy Rating

Aldeyra Therapeutics (ALDX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on...

3M ago

ALDX

Aldeyra Therapeutics: Buy Rating Backed by Promising Phase 3 Results and Strategic Partnerships

Matthew Caufield, an analyst from H.C. Wainwright, reiterated the Buy rating on Aldeyra Therapeutics (ALDX – Research Report)....

3M ago

ALDX

ALDX FAQ

What was Aldeyra Therapeutics’s price range in the past 12 months?

Aldeyra Therapeutics lowest stock price was $1.14 and its highest was $7.20 in the past 12 months.

What is Aldeyra Therapeutics’s market cap?

Aldeyra Therapeutics’s market cap is $322.84M.

When is Aldeyra Therapeutics’s upcoming earnings report date?

Aldeyra Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 256 days.

How were Aldeyra Therapeutics’s earnings last quarter?

Currently, no data Available

Is Aldeyra Therapeutics overvalued?

According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aldeyra Therapeutics pay dividends?

Aldeyra Therapeutics does not currently pay dividends.

What is Aldeyra Therapeutics’s EPS estimate?

Aldeyra Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aldeyra Therapeutics have?

Aldeyra Therapeutics has 59,895,588 shares outstanding.

What happened to Aldeyra Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Aldeyra Therapeutics?

Currently, no hedge funds are holding shares in ALDX

Aldeyra Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-65.91%

Trailing 12-Months

Asset Growth

-32.59%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. (ALDX) is a biotechnology company engaged in the development of innovative therapies for immune-mediated diseases. The company's core focus is on the identification and development of drugs that alleviate inflammation and other related conditions by targeting reactive aldehyde species, which are implicated in numerous diseases. Aldeyra's product pipeline includes treatments for conditions such as dry eye disease, allergic conjunctivitis, and non-infectious anterior uveitis.

Aldeyra Therapeutics (ALDX) Earnings & Revenues

Historic Earnings Reports

ALDX Stock 12 Month Forecast

Average Price Target

$9.50

▲(76.25% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","3.5":"$3.5","8.5":"$8.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.5,6,8.5,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.81,5.209230769230769,5.608461538461539,6.007692307692308,6.406923076923077,6.806153846153846,7.205384615384615,7.604615384615385,8.003846153846155,8.403076923076924,8.802307692307693,9.201538461538462,9.600769230769231,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.81,5.17076923076923,5.531538461538461,5.892307692307692,6.2530769230769225,6.613846153846153,6.974615384615385,7.335384615384616,7.696153846153846,8.056923076923077,8.417692307692308,8.778461538461539,9.13923076923077,{"y":9.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.81,5.132307692307692,5.454615384615384,5.776923076923077,6.099230769230769,6.421538461538462,6.743846153846153,7.066153846153846,7.388461538461538,7.71076923076923,8.033076923076923,8.355384615384615,8.677692307692308,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.22,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.27,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.2,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.71,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.29,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.82,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.99,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.11,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.48,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.81,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >